1. Introduction {#s0005}
===============

Breast cancer has implications in excess women mortality rates, the main reasons of it being lack of safer, effective, non-toxic and potent treatment options ([@b0170]). In the United States, there were 40,290 breast cancer related deaths seen during 2015, more than 2.8 million breast cancer women cases were identified during 2016, among which 40,610 were estimated to die at the end of 2017, and around 255,180 new cases will be diagnosed ([@b0060]). Breast cancer majorly occurs due to genetic mutations (85%) specifically mutations of *BRCA1* and *BRCA2* genes. There are mounting evidences that natural products that are currently used in traditional medicinal system, possess a wider range of chemical diversity and potential to be the source for modern drug discovery ([@b0120]), because natural bioactive molecules are curative as compared to inherently destructive chemotherapy and cytotoxic drugs ([@b0285]). This has lead deep passion among scientists towards identification of pharmaceutically important novel plant based compounds as compared to synthetic drugs that could intervene to modulate different signalling cascades so as to circumvent breast cancers ([@b0050], [@b0285]). Although, breast cancer related mortality incidences have declined to some extent due to currently employed therapies such as selective radiotherapy, chemotherapy, estrogen receptor modulators (or SERMs) in the form of tamoxifen, raloxifene and class of aromatase inhibitors (letrozole, exemestane, anastrozole). However, not all races are getting benefitted from such aggressive therapies because, the patients generally relapse or suffer from side effects such as menopausal complications, blood clots, osteoporosis, etc ([@b0090]). It is an established fact that an alternative mode of treatment is vital either singly or in combinatorial drug regimen against breast cancers ([@b0060]). These grim facts and figures tempt scientists to desperately look for newer, safer, cheaper and potent natural sources of anticancer drugs that were being used in different ethno-medicinal systems from past several centuries due to their better tolerability ([@b0290]). These measures if proved scientifically will result to tackle this unmet medical condition using alternative natural drug therapy.

*Crocus sativus* L. (*Crocus sativus* var. Cashmerianus Royle) is considered as a legendary, highly remunerative cash crop, being source of luxury spice known as saffron. Among the world's total saffron production of 205 tons, Iran contributes 160 tons (\~80%), Jammu and Kashmir, India contributes around 8--10 tons (\~5%), Greek 4--6 tons (\~3%), Morocco 0.8--1 ton (\~0.5%), Spain 0.3 to 0.5 ton (\~0.25%) and rest is contributed by other countries ([@b0100]). It is economically very important medicinal spice, possessing fabulous ethno-pharmacological potential. Saffron plant has a rich history of being used in various folk medicinal systems (Traditional Indian, Iranian and Azerbaijani) to cure or prevent different types of diseases including cancer ([@b0255], [@b0215], [@b0135], [@b0160]). The production of small quantity of saffron leave behind huge quantities of least priced bio-wastes in the form of tepals, leaves, stamen etc. These bio-wastes could play source of lead compounds for food and pharmaceutical industries, as they have potential medicinal properties including cytotoxic, antioxidant, antifungal etc. ([@b0210]). The outcome of proper scientific evaluation of different organs of this species is anticipated to find new bioactive molecules against various cancer types, as they possess different types of yellowish carotenoids (Crocins). Crocin molecules being the main constituent of saffron extract is a family of carotenoids that constitutes 6--30% in terms of saffron total dry matter, the concentration of which depends upon growing conditions**,** variety and processing methods ([@b0195], [@b0215]). Apart from stigmatic portion of *C. sativus* which is an important source of bioactive constituents, there is a growing zeal among natural product researchers to study other least explored tissue types of this plant species including leaves so as to isolate the potential phytocompounds responsible for anticancer properties ([@b0225], [@b0185]).

There are marvellous biological properties attributed towards crocin(s) such as antioxidant, as it increases glutathione peroxidase and superoxide dismutase activity that helps in the detoxification of free radicals ([@b0030]) also these molecules act as chemo preventive agents ([@b0030]). Moreover, crocins reported much effective against wide range of malignant cells both *in-vitro* and *in-vivo* e.g. HeLa, HL60 ([@b0020], [@b0140], [@b0145]), MCF-7, MDA-MB-231, adenocarcinoma HT-29 ([@b0195]), AGS-gastric adenocarcinoma ([@b0040]), HT-29, Caco-2, CEM/ADR5000, HepG2, LAPC-4, CWR22, DU145, L1210/P3888 Leukemia, Sarcoma S-180, HT-29, C26 colon carcinoma, BxPC-3, TC-1, SKOv3, A549 ([@b0035], [@b0030]). Hence, crocins molecules possess important biological properties such as antioxidant, anticancer, chemo prevention etc. ([@b0180], [@b0195], [@b0035], [@b0165]). Crocins do not compromise safety of normal cells as they are non-toxic and non-mutagenic agents with potential to treat different cancer types by modulating various signalling pathways ([@b0005], [@b0040], [@b0200]).

Crocin and crocetin exist in *Crocus*. They are the chemical components with antioxidative properties primarily responsible for the color of the stigmas of *Crocus sativus* L. (Saffron). Crocetin is a carotenoid dicarboxylic acid with 20 carbon atoms and it is the core of crocin. Crocin, in general term, includes Crocin-I (Crocetin-di-beta -D-gentiobiosyl ester), Crocin-II (Crocetin-beta-D-gentiobiosyl-beta-[d]{.smallcaps}-glucosyl ester), Crocin-III (Crocetin-mono-beta-D-gentiobiosyl ester), Crocin-IV (beta-D-monoglucoside ester of monomethyl alpha-crocetin), Crocetin-di-(beta-[d]{.smallcaps}-glucosyl) ester, Crocetin-mono-beta -[d]{.smallcaps}-glucosyl ester. Crocin mainly exists in *trans*-form, but can also present in *cis*-form in minor amount. Crocetin beta-[d]{.smallcaps}-glucosyl ester has antioxidant properties, ([@b0030]) also these molecules act as chemo preventive agents ([@b0030]). Moreover, Crocetin have been reported to act against malignant cells both *in-vitro* and *in-vivo* e.g. HeLa, HL60 ([@b0020], [@b0140], [@b0145]),

Estrogen receptor alpha has potent implications breast cancer which is quite evident from the fact that it is over-represented in majority of such cancers. Estrogen provoked breast cancer signalling is mediated by estrogen receptor alpha and due to these reasons this receptor has remained the central focus in anti-estrogen breast cancer therapy. Besides breast cancer signalling is epigenetically fuelled by HDAC2 over activity. On the whole these findings suggest that estrogen receptor alpha and HDAC2 are the promising targets for breast cancer drugs and therapy. Taking these grim facts into account we selected these two receptors for our molecular docking and binding affinity studies.

It is important to validate the ethno-medicinal properties of plant derived drugs, because there is a huge scientific and industrial interest mushrooming within pharmaceutical domain to isolate and characterize plant based bioactive compounds including carotenoids (Crocins) that could open up novel ways to treat and prevent cancer incidences specifically breast cancers ([@b0250]). Saffron plant has a rich history of being used as a folklore medicine to prevent and treat different diseases including cancers which has been recently studied through various scientific evidences ([@b0195], [@b0160]). Therefore, the current study attempted to isolate and characterize crocin(s) from leaves of *Crocus sativus* which are considered to be the major and cheaper biowastes of saffron industry. The antioxidant and antiproliferative properties were undertaken using *in-vitro* and *in-silico* based combinatorial approach.

2. Materials and methods {#s0010}
========================

2.1. Plant material collection, authentication and processing {#s0015}
-------------------------------------------------------------

The leaves of *Crocus sativus* var*. Cashmerianus* were collected from saffron karewas of Pampore Kashmir, India (1574 m above sea level) during March 2019 and were shade dried. The authentication of sample was done by an expert taxonomist and the voucher specimen of the same was deposited at Kashmir university herbarium (KASH) under accession number KASH-1733. The dried samples were subjected to grinding into fine powder and phytochemical extraction through maceration was carried out using petroleum ether as an organic solvent ([@b0290]).

2.2. Chemicals and solvents {#s0020}
---------------------------

The chemicals and reagents including 2,2-diphenyl-1-picrylhydrazyl (DPPH), 3-(4,5--dimethyl thiazol--2--yl)--5--diphenyltetrazolium bromide (MTT) were procured from Sigma Aldrich, USA. Pre-coated TLC aluminum sheets from Analtech, Inc, Germany. 60--120 mesh size silica gel, Fetal Bovine serum (FBS), Phosphate Buffered Saline (PBS), Dulbecco's Modified Eagle's Medium (DMEM), Trypsin. EDTA, Glucose, MHA medium, PDB medium, solvents and antibiotics were procured from Hi-Media Laboratories Ltd., Mumbai. UV--Vis spectrophotometer (Chemito Technologies, India), FT-IR spectrums (Perkin Elmer, MA, USA), NMR spectrometer (Bruker) and mass spectra's were recorded using WATERS-Q-TOF Micromass.

2.3. Biological materials and culture medium {#s0025}
--------------------------------------------

MCF-7 (Human breast carcinoma cell line) and L-6 (Normal rat muscle cell line) were obtained from National Centre for Cell Sciences (NCCS), Pune, India. DMEM medium containing 10% inactivated Fetal Bovine Serum (FBS), streptomycin (100 g/ml), amphotericin B (5 g/ml) and penicillin (100 IU/ml) with humidified atmosphere of 5% CO~2~ was maintained at 37 °C until confluent and was used for the culture of cell stock. Later, the dissociation of the cells was done using TPVG (Trypsin Phosphate Versene Glucose) solution containing 0.2% trypsin, 0.02% EDTA, 0.05% glucose in PBS and 25 cm^2^ culture flasks were used to grow the stock cultures.

2.4. Localization, isolation and purification of Crocin (s) {#s0030}
-----------------------------------------------------------

Bioautography: The identification of biologically active compounds was localized by DPPH/antioxidant TLC bioautography assay ([@b0070], [@b0265]). Briefly extract was applied on TLC plates as a spot using capillary tube at the concentration of 100 µg/ml. The plates were dried, immersed in 0.2% DPPH solution in methanol and left for half an hour. The appearance of white, yellow spots against a purple background indicates antioxidant activity. The isolation of crocetin beta-[d]{.smallcaps}-glucosyl ester using column chromatography, followed by preparative thin layer chromatography on pre-coated TLC plates of 20 × 20 cm ([@b0150]). Briefly, a glass column of 5 cm diameter and 70 cm length was packed with activated 400 g silica gel slurry (Silica gel was dried at 100 C with mesh size of 60--120; Merk India) dissolved in petroleum ether. The crude extract (10 g) was dissolved in minimum quantity of toluene, followed by adsorption onto 20 g of silica gel, the solvent was allowed to evaporate and then the silica bound sample was placed at the top of the already packed silica gel column. The mobile phase toluene: acetone: water: acetic acid (16:2:2:2) was allowed to elute the column using increase in polarity in different ratios at fraction of 5 ml volume were collected, evaporated using rotary evaporator at controlled temperature of 40--50 °C. The identity of the fractions was examined by TLC on silica gel coated aluminum sheets (UV 254, Macherey/Nagel GmbH & co. Duren Germany). The developed plate was dried, exposed to iodine vapors (spots marked) and finally derivatized with anisaldehyde reagent (10 ml sulphuric acid + ice cooled mixture of methanol & 20 ml acetic acid + 1 ml anisaldehyde). The fractions that showed the same UV/Vis spectrum ([@b0070]) as well as same TLC development profiles (Color and RF Value) were pooled together and concentrated to dryness under reduced pressure using rotary evaporator. The column sub fractions were purified using preparative pre-coated TLC plates via bioautography approach. The experiment was repeated several times till the purity of the compound was assured by aiming that compound is present as a single spot.

The identification of biologically active compounds were localized by DPPH-Antioxidant TLC Bioautography assay ([@b0070], [@b0265]). The isolation of crocetin beta-[d]{.smallcaps}-glucosyl ester was carried out using preparative thin layer chromatography on pre-coated TLC plates of 20 × 20 cm and also by silica gel based column chromatography ([@b0150]). All the scrapped spots were collected and dissolved in highly soluble solvents (ethanol, methanol and DMSO). The solution was subjected to centrifugation to remove silica gel pellet, supernatant was collected and solvent evaporated using rotary evaporator. The physical properties of purified compounds were noted down e.g. color, solubility &R~f~ values.

2.5. Structural elucidation of Crocin(s) {#s0035}
----------------------------------------

The purified molecule was characterized for structural elucidation using various spectroscopic hyphenated techniques such as FT-IR ([@b0025]), UV--Vis ([@b0085]), NMR ([@b0305]), MS-MS ([@b0150], [@b0220]) and the data was compared with previously published literature.

2.6. Free radical scavenging (DPPH) bioautography assay {#s0040}
-------------------------------------------------------

The antioxidant activity of isolated compound was further tested using TLC based qualitative assay described by [@b0265] with minute modifications. Briefly, respective compounds were applied on TLC plates as a spots using capillary tubes at the concentration of 100 µg/ml. The plates were dried, immersed in 0.2% of DPPH solution in methanol and left for half an hour. The appearance of white-yellow spots against a purple background indicates antioxidant activity.

2.7. Antiproliferative assay {#s0045}
----------------------------

Cytotoxicity studies were performed by MTT assay as described in the previous literature ([@b0265]). Briefly, Crocetin beta-[d]{.smallcaps}-glucosyl ester small molecule was dissolved in distilled DMSO (0.1%) and stock solution of 1 mg/ml concentration was made using DMEM supplemented with 2% inactivated FBS. The solution so obtained was sterilized by filtration. The serial dilutions were made to prepare different concentrations of the extract (31.25, 62.5, 125, 250, 500, 1000 µg/ml) to carry out cytotoxic studies. The monolayer cell culture was trypsinized and using DMEM containing 10% FBS, the cell count was adjusted to 1.0 × 10^5^ cells/ml. 0.1 ml of the diluted cell suspension (approximately 10,000 cells) was added to each well of the 96 well microtitre plate, and DMSO (0.1%) without crocetin beta-[d]{.smallcaps}-glucosyl ester was considered as negative control, the cell suspension was kept at 37 °C for 24 h. The supernatant was flicked off and monolayer so obtained was once washed with medium followed by addition of 100 µl of different test concentrations to the partial monolayer in microtitre plates (Tarsons India Pvt. Ltd., Kolkata, India). The plates were then incubated at 37 °C for 72 h in 5% CO~2~ atmosphere and observations were noted every 24 h interval using microscopic examination (20×). The solution in the wells was discarded after 3 days of incubation and to each well 50 µl of MTT in PBS was added. The plates were then gently shaken and incubated for 3 h at 37 °C in 5% CO~2~ atmosphere. The supernatant obtained was discarded first and then 100 µl of propanol was added. In order to solubilise the formed formazan, the plates were gently shaken and absorbance was measured using a microplate reader at a wavelength of 540 nm. The percentage growth inhibition was calculated using the following formula and the concentration of test sample needed to inhibit cell growth by 50% (IC~50~) values was generated from the dose--response curves for both the cell lines (MCF-7 and L-6). All the experiments were carried out in triplicates (n = 3)% Growth inhibition = 100 − ([Mean OD of individual test group]{.ul} × 100)Mean OD of control group

2.8. Ligand preparation {#s0050}
-----------------------

All the ligand molecules were retrieved from PubChem with PubChem CID of 449,459 for 4-hydroxytamoxifen and10368299 for crocetin beta-[d]{.smallcaps}-glucosyl ester. The ligand molecules were prepared using the LigPrep of Maestro v11.0 of Schrodinger tool ([@b0295], [@b0300]). The ligands were minimized and protonation states were generated using the Epik ([@b0275]). Moreover, the ligand molecules were desalted and specified chiralities were retained ([@b0115]). For ligands going to be docked against metalloenzyme HDAC2, metal binding states were also generated.

2.9. Protein preparation {#s0055}
------------------------

The crystal structures of estrogen receptor alpha and HDAC2 were retrieved from Protein Data Bank with PDB ID 3ERT ([@b0280]) and 4LY1 respectively ([@b0175]). The protein preparation was done by Shrodinger package (Protein Preparation wizard) to certify correctness of the structure ([@b0155], [@b0270]). The hydrogen atoms which were missing were added to these structures and bond orders were properly assigned. The Shrodinger package was utilized to fill the side chains and loops which were missing in the protein ([@b0210], [@b0185]). Every molecule of water beyond 5 Å was deleted. In the subsequent steps, the redundant protein chains and heteroatoms were also removed. However, the cocrystallized ligands were retained in both structures for subsequent use in grid generation ([@b0210]). Moreover, in HDAC2, the heteroatom Zinc was retained as it serves as a cofactor for the given enzyme. In the next step the structures were optimized, water molecules making less than 3 hydrogen bonds with non-waters were deleted and the structures were subjected to minimization where heavy atoms were converged to 0.30 Å ([@b0130]). In case of both structures grid was specified using the co-crystallized ligand as centroid.

2.10. Pose validation by self-docking {#s0060}
-------------------------------------

The Protein preparation wizard was employed to prepare estrogen receptor alpha along with its cocrystallized ligand until minimization. Then the separation of the ligand was done and the ligand was redocked to estrogen alpha receptor using the protocol of extra precision flexible docking and the calculation of the root mean square deviation (RMSD) between the native and docked pose was carried out ([@b0260]).

2.11. Molecular docking {#s0065}
-----------------------

The ligands that were prepared were docked against the grid specified receptors using the extra precision flexible docking protocol. Glide (Grid-based Ligand Docking with Energetics) program of Schrödinger package (Glide v7.3) was used to perform molecular docking ([@b0110]). The docked scores were obtained from the pose viewer files of docked complexes.

2.12. Molecular mechanics generalized born surface area (MMGBSA) {#s0070}
----------------------------------------------------------------

The binding free energy (BFE) of inhibitors was calculated by using an implicit solvation model, MMGBSA. The docked complexes were used as input and no flexibility was given to receptor (frozen condition. Prime MM-GBSA makes five important energy calculations namely optimized free receptor (Receptor), optimized free ligand (Ligand), optimized complex (complex), receptor from optimized complex, ligand from optimized complex ([@b0190]). From these energies, MMGBSA free energy of binding is calculated as:MMGBSA dG Bind = Complex − Receptor − Ligand.

3. Results {#s0075}
==========

3.1. Isolation and characterization of \[crocetin (β-[d]{.smallcaps}-glucosyl) ester\]/Crocetin beta-[d]{.smallcaps}-glucosyl ester {#s0080}
-----------------------------------------------------------------------------------------------------------------------------------

Analytical thin layer chromatography (TLC) lead identification of ideal mobile phase (Toluene: acetone: water: acetic acid in the ratio of 16:2:2:2) which gave maximum separation of bands in the crude leaf extracts of *Crocus sativus* ([Fig. 1](#f0005){ref-type="fig"}A). The crude petroleum ether extract was subjected to column chromatography using solvents of differential polarities starting from non-polar towards molar polarity index. The polarity of the solvent was increased step up step by 10% towards more polarity index. Seven different fractions so obtained were tested for antioxidant activity, however only one fraction showed marked antioxidant activity against DPPH free radical ([Fig. 1](#f0005){ref-type="fig"}B) Post preparative TLC, the study ended up with isolation of a yellow coloured compound from the leaves of *C. sativus.* The weight of compound so obtained was found as 17 mg with R~f~ value as 0.53. The solubility of purified compound was verified using ethanol, methanol and DMSO, it dissolves completely in all these solvents.Fig. 1(A) TLC separation of petroleum ether leaf extract of *Crocus sativus* using mobile phase Toluene: acetone: water: acetic acid (16:2:2:2), (B) Antioxidant TLC Bio autography assay of crocetin beta-[d]{.smallcaps}-glucosyl ester using DPPH as free radical.

UV--Vis-spectral data has showed various characteristics absorption bands ([Fig. 2](#f0010){ref-type="fig"}A) between 226 and 500 nm i.e. λmax at 260 nm and 437 corresponds to glucosyl ester bonds and all-*trans*-carotenoids respectively. The FT-IR showed bands at wavelength of 3432 cm^−1^ assigned to hydroxyl groups (---OH), 2921, 1463 and 1376 cm^−1^ for C---H, 1728 cm^−1^ for carbonyl group (C000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000O), 1623 cm^−1^ for CC group, 1071 cm^−1^ for C---O sugar groups ([Fig. 2](#f0010){ref-type="fig"}B). The ^1^H NMR spectrum of molecule in DMSO solution showed the presence of terminal methyl groups by exhibiting signals at *δ* 0.89, methylene groups at *δ* 1.29 and methyl groups attached to the double bonds by exhibiting signals at *δ* 1.56. Further the bunch of signals between *δ* 3.00 and 4.00 are due to protons present in the sugar residue. The signals at *δ* 4.5 and 5.5 are due to the anomeric protons. The couple of signals between *δ* 6.0 and 7.5 are due to unsaturated protons of crocins. In ^1^H--^13^C heteronuclear single quantum coherence (HSQC), signals at *δ* 14.00 for methyl carbon, between *δ* 20 and 40 for the carbon atoms attached to the double bond, between *δ* 50 and 80 for the sugar carbons ([Fig. 2](#f0010){ref-type="fig"}C and D). The scan for mass spectrum was run in positive ion mode and molecular mass of isolated compounds was found as 490. Molecular ion EI-MS^+^ (Mass spectroscopy) was observed at *m*/*z* = 513 (\[M+Na\]^+^) along with an additional signal at *m*/*z* 328 \[(M+H)-Glc\]^+^ ([Fig. 2](#f0010){ref-type="fig"}E). The molecule ([Fig. 3](#f0015){ref-type="fig"}-PubChem CID-10368299) is identified as crocetin beta-[d]{.smallcaps}-glucosyl ester/\[crocetin (β-[d]{.smallcaps}-glucosyl)ester\].Fig. 2A Spectrums of crocetin beta-[d]{.smallcaps}-glucosyl ester based on hyphenated spectroscopic techniques (A) UV--Vis (B) FT-IR (C) ^1^H NMR (D) ^13^C NMR (E) Mass spectrum (ESI^+^). The interpretation of the obtained data along with its comparison with literature data has characterized the compound as \[crocetin (β-[d]{.smallcaps}-glucosyl) ester\] (Molecular formula = C~26~H~34~O~9~).Fig. 3Structure of crocetin (β-[d]{.smallcaps}-glucosyl) ester retrieved from Pubchem (CID-10368299).

3.2. Crocetin beta-[d]{.smallcaps}-glucosyl ester as a significant antioxidant and anticancer agent {#s0085}
---------------------------------------------------------------------------------------------------

The antioxidant activity has revealed appearance of white-yellow spots against purple background on TLC antioxidant bioautographic plates, indicating significant antioxidant property ([@b9000]). The antiproliferative activity of crocetin beta-[d]{.smallcaps}-glucosyl ester against MCF-7 cell line has showed statistically significant inhibitory effect in a dose dependent way with IC~50~ value of 628.36 ± 15.52 µg/ml (*P \< 0*.001) ([Table 1](#t0005){ref-type="table"}). The percentage cytotoxicity effect ranged from 18.5 ± 0.8% to 61.57 ± 1.90% at different concentrations of crocetin beta-[d]{.smallcaps}-glucosyl ester molecule (31.25--1000 µg/ml). The microscopic examination has revealed that crocetin beta-[d]{.smallcaps}-glucosyl ester treated MCF-7 cells have showed cellular apoptotic characteristics such as cell shrinkage, reduced cytoplasm, cytoplasmic vacuole like areas, pyknotic nuclei, nuclear condensation and fragmentation (altered nuclear morphology), while as L-6 cell line has intact cell distribution along with no-marked apoptotic or anti-proliferative characteristics ([Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}).Table 1Cytotoxicity effect of *Crocus sativus* derived Crocetin beta-[d]{.smallcaps}-glucosylesteron on MCF-7 cell line.Compound nameTest conc. (µg/ml)% Cytotoxicity[\*](#tblfn1){ref-type="table-fn"} MCF-7IC~50~(µg/ml)[\*](#tblfn1){ref-type="table-fn"} MCF-7% Cytotoxicity[\*](#tblfn1){ref-type="table-fn"} L-6IC~50~(µg/ml)[\*](#tblfn1){ref-type="table-fn"} L-6\[crocetin (β-[d]{.smallcaps}-glucosyl) ester\]100061.57 ± 1.90628.36 ± 15.5221.80 ± 0.90\>100050047.89 ± 2.021.45 ± 1.225040.78 ± 0.9520.8 ± 0.7512535.46 ± 1.220.45 ± 0. 562.524.34 ± 1.017.89 ± 1.3231.2518.5 ± 0.817.20 ± 0.45[^1]Fig. 4Cytotoxicity effect of \[crocetin (β-[d]{.smallcaps}-glucosyl) ester\] on cells from MCF-7 cell line. The cells were seeded in 96-well plate (10,000 cells/well) for 24 h, then exposed to 0.1% DMSO based extract of \[crocetin (β-[d]{.smallcaps}-glucosyl) ester\] 1 for 72 h at different concentrations (31.25, 62.5, 125, 250, 500, 1000 µg/ml). The statistically significant concentration dependent cytotoxicity (*P* value = 0.0019) was observed with IC~50~ as 628.36 µg/ml. Data are representative of three independent experiments (mean ± SD). Representative slides of MTT assay for MCF-7 cell line upon treatment with \[crocetin (β-[d]{.smallcaps}-glucosyl) ester\]. The prominent morphological changes are seen in treated cells at concentration gradient of 250, 500, 1000 µg/ml, representing apoptosis. L-6 cell line has not demonstrated any significant levels of cytotoxicity upon treatment by \[crocetin (β-[d]{.smallcaps}-glucosyl) ester\] at 500, 1000 µg/ml concentrations with IC~50~ \> 1000 µg/ml. Untreated MCF-7 and L-6 cells act as negative control without any morphological variations. Data are representative of three independent experiments (mean ± SD).Fig. 5Relationship between dose of \[crocetin (β-[d]{.smallcaps}-glucosyl) ester\] and % cytotoxicity against MCF and L-6 cell lines at different concentrations (31.25, 62.5, 125, 250, 500, 1000 µg/ml). The statistically significant concentration dependent cytotoxicity (*P* value = 0.0019) was observed with IC~50~ as 628.36 µg/ml. Non-significant levels of cytotoxicity was observed in L-6 cell line.

3.3. Molecular docking simulation studies showed crocetin beta-[d]{.smallcaps}-glucosyl ester shows stronger affinity against estrogen receptor alpha {#s0090}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Before performing molecular docking studies, it is mandatory to validate algorithm for reproducing the crystal pose of ligand. We performed self-docking as described in methods and computational details. The redocked and native pose presented and RMSD of 1.9341 Å thus validating the accuracy of our algorithm to generate correct pose ([@b0115]) ([Fig. 6](#f0030){ref-type="fig"}). Molecular docking is regarded as the central facet in drug discovery. Our studies showed crocetin beta-[d]{.smallcaps}-glucosylester inhibits the defined receptor as evidenced by the docking score of −6.9 against the defined receptor ([Table 2](#t0010){ref-type="table"}). Crocin −1 showed affinity towards HDAC2 receptor as determined by a docking score of −6.61.Fig. 6Pose validation by self-docking. The native ligand of crystal structure was redocked to its host receptor using extra precision flexible docking protocol. The RMSD between native (pink) and redocked (yellow) pose of ligand was found to be 1.9341 Å clearly suggesting that docking algorithm is working correctly.Table 2Docking scores of Crocetin beta-[d]{.smallcaps}-glucosyl esteragainst estrogen receptor alpha and HDAC2.LigandReceptorDocking scoredGBind(Kcal/mol)4-hydroxytamoxifenEstrogen receptor alpha−14.58−134.1Crocin-1−6.53−80.3Crocin-1HDAC2−6.61−61.7441

3.4. Binding free energy calculation confirmed the predictions of molecular docking {#s0095}
-----------------------------------------------------------------------------------

The relative binding affinity of ligands especially of a congeneric series is calculated by MMGBSA, an implicit solvation model ([@b0115], [@b0155]). Crocin −1 showed BFE value of −80.3 Kcal/mol towards estrogen receptor alpha. The binding free energy value of (−61.7441 Kcal/mol) against HDAC2 was shown by the defined inhibitor ([Table 2](#t0010){ref-type="table"}).

3.5. Crocetin beta-[d]{.smallcaps}-glucosyl ester shows similar but not identical interaction profile as that of 4-hydroxytamoxifen {#s0100}
-----------------------------------------------------------------------------------------------------------------------------------

In order to gain insights regarding the interaction profile of crocetin beta-[d]{.smallcaps}-glucosyl ester against estrogen receptor alpha we generated ligand--protein contacts up to 4 Å from docked complexes. While 4-hydroxytamoxifen showed 3 hydrogen bonding interactions with Arg 394, Glu 353, Asp 351, crocetin beta-[d]{.smallcaps}-glucosyl ester portrayed 4 hydrogen bonding interactions with Arg 394, Leu 536 and Glu 380 ([Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}, [Fig. 8](#f0040){ref-type="fig"}). In case of HDAC2 crocetin beta-[d]{.smallcaps}-glucosyl ester formed one hydrogen bonding interaction with Pro 211 and one salt bridge with Arg 39 ([Fig. 9](#f0045){ref-type="fig"}).Fig. 7Residues of estrogen alpha receptor targeted by 4-Hydroxytamoxifen. This inhibitor targets Arg 394, Glu 353 and Asp 351 by forming hydrogen bonding interactions with them.Fig. 8Residues targeted by Crocetin beta-[d]{.smallcaps}-glucosyl ester in estrogen receptor alpha. \[crocetin (β-[d]{.smallcaps}-glucosyl) ester\]-1 forms hydrogen bonding interaction with residues Glu 380, Leu 536 and Arg 394. Moreover, the defined inhibitor forms a salt bridge with Arg 394.Fig. 9Crocetin beta-[d]{.smallcaps}-glucosyl ester targets HDAC2 residue Pro 211 by forming hydrogen bonding interaction with it and Arg 39 by forming salt bridge.

4. Discussion {#s0105}
=============

Globally, breast cancer is the most common cancer type causing cancer related deaths in huge numbers among women and this is the second most cancer type in general. Since 2008 onwards breast cancer induced mortality rate has increased by 14%. Although several dozens of synthetic anticancer drugs have been discovered till date like tamoxifen, raloxifene and class of aromatase inhibitors. Nevertheless, with these treatments patients generally relapse or suffer from side effects such as menopausal complications, blood clots, osteoporosis etc ([@b0090]). In contrary, natural products are generally seen as lesser toxic, effective and cheap. The screening of such potential bioactive molecules against breast cancer can open up novel gateway to tackle such therapeutically challenging disease.

There are many plant based potential molecules currently being used in the pharmaceutical industry and about 60% of anti-tumor and anti-infectious drugs which are prescribed worldwide come from plants like vincristrine/vinblastine from *Catharanthus roseus* ([@b0245]). *Crocus sativus* is source of saffron which is a repository of complex molecules like carotenoids (Crocin, picrocrocin and safranal), glycosides, monoterpenes, aldehydes, anthocyanins, flavonoids, vitamins, amino acids, starch, mineral matter, proteins, gums ([@b0105]), chitinase Safchi A ([@b0075]) and other compounds present in saffron could be responsible for different properties including antioxidant, anticancer, anti-bacterial, antidiabetic, analgesic, aphrodisiac, sedative, anti-alzheimer's, anti-tussive, anti-convulsant ([@b0045], [@b0205], [@b0010]). There are no toxicity reports associated with proper usage of saffron or its extracts because hematological and biochemical studies on the toxicity of saffron has showed that there are no signs of any toxicity found in kidney, liver or bladder ([@b0125]). The previous studies have specified the importance of *Crocus sativus* in traditional and modern therapy including its major components in the form of crocin(s) ([@b0250], [@b0160], [@b0235]). However, the biologically active crocin (s) have been isolated from stigmatic portion of saffron plant which is economically a costlier source. The current study therefore attempted to isolate and characterize a bioactive molecule from leaves of saffron plant in the form of crocetin beta-[d]{.smallcaps}-glucosyl ester which is a cheaper source. UV--Vis, FT-IR, NMR and mass spectrum of isolated molecule were compared with previous studies which confirmed this molecule as Crocetin beta-[d]{.smallcaps}-glucosyl ester ([@b0085], [@b0065]). Based on the interpretation of obtained spectral data along with its comparison with literature data, we proposed the molecular formula of isolated compound as C~26~H~34~O~9~ ([Fig. 2](#f0010){ref-type="fig"}). This small molecule of crocetin beta-[d]{.smallcaps}-glucosyl ester is identified and characterized for the first time from cheaper sources (leaves) of *C. sativus* using hyphenated spectroscopic techniques ([Fig. 3](#f0015){ref-type="fig"}). Crocetin beta-[d]{.smallcaps}-glucosyl ester has demonstrated significant inhibitory activity against MCF-7 cell line without affecting normal cell line (L-6). Strong strong inhibitory effect of saffron crude extracts against MCF-7 cell lines has been observed earlier with IC~50~ value between 350 and 400 µg/ml ([@b0080]) which could be due to synergistic effect of multiple compounds present in crude extract. The current investigation has successfully been able to prove that the main chemical player responsible against breast cancer cell lines is Crocetin beta-[d]{.smallcaps}-glucosyl ester. The intricate molecular mechanism of crocin molecules against breast cancer is globally still enigmatic, but the most accepted mechanism is that the sugar moiety of crocin(s) plays a vital role in its chemical activities due to in-tense electrostatic potential terminals which makes it as a trap for free radicals. There are other proposed mechanisms of crocin acting against different malignant human cell lines e.g. it strongly binds to histone H1 which induce unknown conformational changes that decreases the interaction between H1 protein with DNA ([@b0020]). Crocin increases tubulin polymerization and microtubule nucleation rate in a concentration dependent manner and it showed downregulation of cyclin D1, p21 and p53 which occurs in breast tumor induced by NMU injection in female rat. They also induce tumor cell apoptosis by down regulating the expression of B-cell lymphoma/leukemia-2 (Bcl-2), survivin, cyclin D1 and up regulating the expression of Bax (decrease Bcl-2/Bax ratio). The action of saffron extract on breast cancer cell line MCF-7 could be by induction of caspase-dependent pathway and exerts proapoptotic effects ([@b0110]). The evidence of antiproliferative activity of saffron derived crocin molecule against breast cancer cell lines indicates its ethno- pharmacological potential to prevent and treat cancer owing its strong antioxidant potential ([@b0245], [@b0255], [@b0130]). Crocin as a candidate chemopreventive agent against HCC. Crocin exhibited anti-inflammatory properties where NF-κB, among other inflammatory markers, was inhibited ([@b0015]). The folklore medicinal properties of saffron could be thus attributed due to strong radical scavenging activities incoherence with proapoptotic effects. The further evaluation of its clinical use would ameliorate saffron demand which will motivate farmers or traditional healers to promote its cultivation at a large scale, an opportunistic approach would lead its constructive conservation and usage sustainably, a way to assure biodiversity preservation. Structure based drug designing studies showed that crocetin beta-[d]{.smallcaps}-glucosyl ester has stronger affinity against estrogen receptor alpha, while as binding free energy calculation confirmed the predictions of molecular docking. Molecular docking is regarded as the central facet in drug discovery. It predicts the conformation and orientation of ligand within a target binding site ([@b0115]). Moreover, accurate structural modelling and correct prediction of activity are its two main aims. We performed molecular docking simulations against estrogen alpha receptor using 4-hydroxytamoxifen as positive control and crocetin beta-[d]{.smallcaps}-glucosyl ester as experimental molecule. Moreover, HDAC-2 over-expression is also seen in breast cancer so performed docking studies against this enzyme also ([@b0230]). Thus our molecular docking simulations and binding free energy calculations clearly suggest that crocetin beta-[d]{.smallcaps}-glucosyl ester indeed shows affinity towards estrogen receptor alpha and HDAC2 as determined by the negative values of docking score and BFE ([@b0155]). Crocetin beta-[d]{.smallcaps}-glucosyl ester shows similar but not identical interaction profile as that of 4-hydroxytamoxifen and thus it is quite evident that crocetin beta-[d]{.smallcaps}-glucosyl ester shows similar but not identical interaction profile against estrogen receptor alpha. The results of this study could act as a base to provide an alternative natural therapy for mitigation of breast cancer incidences.

This study involved the combinatorial stragey for proving the cytotoxic effect of Crocin-1 against breast cancer model along with the possible underlying mechanism being involved. However, this study shedded no light on the higher order clinical studies which will further support the promsing effect of defined molecules. Thus capacious clinical studies are required to facilitate this molecule from bench to bedside.

5. Conclusions {#s0110}
==============

Based on the facts and information provided in the current research article, it is concluded that C*rocus sativus* leaf derived crocetin beta-[d]{.smallcaps}-glucosyl ester small molecule is effective against DPPH free radical and against MCF-7 breast cancer cell line. The results of this study could also offer an opportunity to use leaves of C*rocus sativus* as cheap source of crocetin beta-[d]{.smallcaps}-glucosyl ester for pharmaceutical industry, this would open up new dimensions to prevent and tackle therapeutically challenging breast cancer cases naturally, economically and elegantly compared to conventional drug therapies. It is recommended here that further *in-vitro* and *in-vivo* vigorous studies regarding dose, safety and toxicity of crocetin beta-[d]{.smallcaps}-glucosyl ester molecule needs to be undertaken before they could enter into different phases of clinical trials, as a potential alternative against breast cancer.
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[^1]: **% Cytotoxicity**: The statistically significant percentage of cell toxicity (p *\< 0.05)* in MCF-7 cells upon progressive increase of dose (31.25, 62.5, 125, 250, 500, 1000 µg/ml). **IC~50~**: Effective concentration of molecules in µg/ml required to achieve 50% growth inhibition of breast cancer cells (MCF-7). Data are representative of three independent experiments (mean ± SD).
